1. ALLA AKTIER
  2. NYHETER
  3. DOUBLE BOND PHARMACEUTICAL

Double Bond Pharmaceutical

Nyheter Double Bond Pharmaceutical Nyheter alla bolag

DBP International AB: European patent for the technology platform BeloGal® is granted

REG

   

Double Bond Pharmaceutical International AB (publ) ("DBP" or the "Company", org. no. 556991-6082) has today, May 29, 2024, received information about the granting of a European patent application for organ-specific administration of hydrophilic cancer drugs to the liver. This applies, among other things, to one of the company's frontline products SA-033 for the treatment of liver cancer, which is based on the technology platform BeloGal®. The patent approval means protection for the product in 26 countries within the European Patent Office (EPO) at least until the year 2035.

"The granted patent concerns the geographically most important market in the world and we have reached an important milestone for the commercialization of our frontline product SA-033 for the treatment of liver cancer," comments Igor Lokot, CEO of Double Bond Pharmaceutical.

More about SA-033: SA-033 is the first drug candidate that DBP has developed using its innovative drug delivery technology BeloGal®. Due to innovative formulation controls targeting of doxorubicin to the liver, the concentration of the active substance in the desired target organ increases, which enhances efficacy and reduces the toxic side effects that are common in systemic chemotherapy.

More about BeloGal®: BeloGal® is DBP’s innovative drug-delivery platform which targets pharmaceutically active compounds to lung or liver.

This disclosure contains information that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 29-05-2024 07:30 CET.

Datum 2024-05-29, kl 07:30
Källa Cision
Bifogade filer
DBP Patent EU BeloGal EN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!